University Nuclear Medicine Ltd is categorized under Health Services in Chicago, IL and active since 2010.
University Nuclear Medicine Ltd was established in 2010, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Health Services business, which does work in the B2C market, and is classified as a Health Services, under code number 621999 by the NAICS.
If you are seeking more information, feel free to contact Robert E Henkin at the company’s single location by writing to 1952 West Cuyler Avenue Apartment 404, Chicago, Illinois IL 60613 or by phoning (630) 268-0611. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | University Nuclear Medicine Ltd |
Contact Person: | Robert E Henkin |
Address: | 1952 West Cuyler Avenue Apartment 404, Chicago, Illinois 60613 |
Phone Number: | (630) 268-0611 |
Annual Revenue (USD): | $100.000 to $499.999 |
Founded: | 2010 |
Location Type: | Single Location |
Employee Number: | 1 to 4 |
Business Type: | B2C (Business to Consumer) |
Business Category: | Health Services |
SIC Code: | 8099 |
NAICS Code: | 621999 |
Share This Business: |
University Nuclear Medicine Ltd was started in 2010 to provide professional Health Services under the SIC code 8099 and NAICS code 621999. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Robert E Henkin for inquiries that concern University Nuclear Medicine Ltd by calling the company number (630) 268-0611, as your correspondence is most welcome. Additionally, the physical location of the single location of University Nuclear Medicine Ltd can be found at the coordinates 41.95523,-87.678599 as well as the street address 1952 West Cuyler Avenue Apartment 404 in Chicago, Illinois 60613.
For its online presence, you may visit University Nuclear Medicine Ltd’s website at and engage with its social media outlets through on Twitter and on Facebook.